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Objective: Peroxisome-proliferator–activated-receptor-γ (PPARγ) acts as a transcriptional regulator of multiple genes
involved in glucose and lipid metabolism. In vitro studies showed that activated PPARγ suppresses AT1R-gene
expression and vice versa. However, it has not yet been determined in vivo, whether AT1R-PPARγ-interactions play
a relevant role in the pathogenesis of diabetic complications and specifically in accelerated atherosclerosis.
Methods and results: ApoE−/− and ApoE−/−/AT1R−/−-mice were rendered diabetic by intraperitoneal injections of
streptozotocin. Diabetic and non-diabetic ApoE−/−-mice were further randomized to receive the AT1R antagonist
telmisartan, the selective PPARγ antagonist GW9662, telmisartan and GW9662 or vehicle for 18 weeks. Diabetic and
non-diabetic ApoE−/−/AT1R−/−-mice were randomized to receive either GW9662 or vehicle. GW9662 treatment in
diabetic ApoE−/− and diabetic ApoE−/−/AT1−/−-mice resulted in the highest elevation of fasting blood glucose
levels, whereas telmisartan treatment and AT1 deficiency in ApoE−/−-mice showed the lowest fasting blood glucose
levels. Diabetic ApoE−/−-mice displayed severe impairment of endothelial function, enhanced oxidative stress and
increased atherosclerotic lesion formation. ApoE−/−/AT1R−/− and telmisartan-treated ApoE−/−-mice showed a
significantly better endothelial function, decreased oxidative stress and reduced atherosclerotic lesion formation.
Treatment of diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice with the selective PPARγ antagonist GW9662 omitted the
atheroprotective effects of AT1R deficiency or AT1 antagonism.
Conclusion: Genetic disruption or pharmacological inhibition of the AT1R attenuates atherosclerosis and improves
endothelial function in diabetic ApoE−/−-mice via the PPARγ pathway.
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Diabetes mellitus is a leading cause of morbidity and mor-
tality in western countries due to cardiovascular complica-
tions [1]. It has been suggested that hyperglycaemia,
insulin resistance, glycation of proteins, oxidative stress
and inflammation may be related to atherogenesis in
diabetes [2]. The metabolic abnormalities associated
with diabetes lead to activation of the renin-angiotensin-
aldosterone system (RAAS) with a subsequent increase of
angiotensin II (Ang II) and increased AT1-receptor (AT1R)
activation [3,4]. Increased AT1R activation promotes for-
mation of reactive oxygen species (ROS) which are in turn* Correspondence: Vedat.Tiyerili@ukb.uni-bonn.de
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reproduction in any medium, provided the orclosely linked to the onset and progression of endothelial
dysfunction and atherogenesis [5]. Inhibitors of the RAAS
system are associated with improvement of insulin sensitiv-
ity, reduced rates of new onset of diabetes and decreased
ROS formation [6-8]. So far, the causal link between these
clinical observations and AT1R inhibition remains unclear.
Some angiotensin receptor blockers (ARBs), such as telmi-
sartan are partial agonists of peroxisome proliferator-
activated receptors (PPARs) [9-11]. The most abundant
isoform, PPARγ, plays an important role in the regula-
tion of adipogenesis and insulin sensitivity [12]. Fur-
thermore, PPARγ activation has been associated with
anti-atherosclerotic effects including reduced forma-
tion of ROS [13]. Beneficial effects of ARBs may be par-
tially attributed to the activation of PPARγ [9]. In vitro
studies investigating the interaction of PPARγ and the
AT1R in vascular smooth muscle cells (VSMC) showedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and vice versa, suggesting that pharmacological blockade
or genetic disruption of the AT1R leads to enhanced
PPARγ activity thereby mediating anti-atherosclerotic
effects in the vascular compartment [14,15]. However, the
relevance of these mechanisms has not been determined
in an in vivo model of diabetes. Whether interactions of
AT1R and PPARγ play a key role in the pathogenesis of
diabetes-induced atherosclerosis remains undetermined.
In the present study we analysed the influence of AT1R-
PPARγ interactions on diabetic-induced atherosclerotic
lesion formation and endothelial function in an experi-
mental long-term diabetic mouse model. In this well char-
acterized model, injection of the cytotoxin streptozotocin
(STZ) results in a reduction in ß-cells and an increase in
plasma glucose to diabetic levels [4]. The validity of this
model has recently been confirmed as appropriate for
the study of diabetes-associated atherosclerosis by the
National Institutes of Health (NIH)/Juvenile Diabetes
Research Foundation (JDRF)-supported Animal Models of
Diabetic Complications Consortium [16]. Our aim was to
determine whether pharmacological inhibition or gen-
etic disruption of the AT1R and the PPARγ pathway
would interfere with the pathogenesis of diabetic vascu-
lar complications.
Methods
Animals and treatment protocols
Female, 6-week-old homozygous apolipoprotein E defi-
cient (ApoE−/−) mice (genetic background: C57BL/6J,
Charles River, Sulzfeld, Germany) and AT1A receptor
knockout mice (AT1R−/−) with identical genetic back-
ground (kindly provided by Dr. Coffmann, University of
North Carolina) were used for this study. Thirty-two
ApoE−/−-mice and 12 ApoE−/−/AT1R−/−-mice were ren-
dered diabetic by 5 daily intraperitoneal injections of strep-
tozotocin (Sigma-Aldrich, Germany) at a dose of 55mg/kg
in citrate buffer or received citrate buffer (0.01 mol/l,
pH: 4.5) alone (Figure 1A). All streptozotocin treated ani-
mals had blood glucose-levels ≥250 mg/dl 14 days after the
induction of diabetes. The same number of ApoE−/−-mice
and ApoE−/−/AT1R−/− served as non-diabetic control ani-
mals (Figure 1A). In addition, diabetic and non-diabetic
ApoE−/−-mice were randomized in 8 groups consisting of 8
animals to receive the AT1R-blocker telmisartan (Sigma-
Aldrich, Germany) at a dose of 40 mg/kg body weight per
day orally via chow or the selective PPARγ antagonist
GW9662 (Sigma-Aldrich) i.p. at a dose of 1mg/kg body
weight every second day or telmisartan and GW9962 or
vehicle for 18 weeks (Figure 1A). Diabetic and non-
diabetic ApoE−/−/AT1R−/−-mice were further randomized
in 4 groups consisting of 6 animals to receive either
GW9662 or vehicle for 18 weeks (Figure 1A). After induc-
tion of diabetes the animals were treated for 18 weeks, hadunrestricted access to water and standard mouse chow and
were maintained in a room with a 12-hour light/dark cycle
and a constant temperature of 22C. The experimental set-
ting is depicted as flow chart in Figure 1B. After treatment
of 18 weeks mice were sacrificed and read-outs were per-
formed (Figure 1B). All animal experiments were per-
formed in accordance with institutional guidelines and the
German animal protection law.
Measurements of blood pressure (BP), heart rate, blood
glucose and body weight
Systolic blood pressure and heart rate were measured by a
computerized tail-cuff system (CODA 6, Kent Scientific)
in conscious animals. Blood glucose levels were measured
using Accu-ChekW-Sensor, Roche, Mannheim, Germany).
Blood samples were collected by tail vein puncture. Body
weights were measured weekly and changes in body
weight at baseline compared to body weight after 18
weeks of treatment were calculated.
Aortic ring preparations and tension recording
After excision of the descending aorta, the vessel was
immersed in chilled, modified Tyrode buffer containing,
in mmol/L, NaCl 118.0, CaCl2 2.5, KCl 4.73, MgCl2 1.2,
KH2PO4 1.2, NaHCO3 25.0, Na EDTA 0.026, D(+) glu-
cose 5.5, pH 7.4. Three-millimeter rings were mounted
in organ baths filled with the above-described buffer
(37C; continuously aerated with 95% O2 and 5% CO2)
and were attached to a force transducer, and isometric
tension was recorded. The vessel segments were grad-
ually stretched over 60 minutes to a resting tension of
10 mN. The drug concentration was increased when
vasoconstriction or vasorelaxation was completed. Drugs
were washed out before the next substance was added.
Staining of atherosclerotic lesions and morphometric
analysis
Hearts with ascending aortas were embedded in Tissue
Tek OCT embedding medium and sectioned on a Leica
cryostat (9 μm), starting at the apex and progressing
through the aortic valve area into the ascending aorta
and the aortic arch and placed on poly-L-lysine (Sigma)
coated slides. At least 15 consecutive sections per animal
were used for analysis. For detection of atherosclerotic
lesions, aortic cryosections were fixed with 3.7% formal-
dehyde and stained with oil red O working solution. For
morphometric analysis, hematoxylin staining was per-
formed according to standard protocols. Stained samples
were examined with a Zeiss Axiovert 200 microscope
(Carl Zeiss Jena, Germany) and an AxioCam MRc5.
Images were acquired with Zeiss AxioVision software
Rel. 4.5.0 and processed with Corel Graphic Suite X4.
For quantification of atherosclerotic plaque formation in
the aortic root, lipid staining area and total area of serial
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Figure 1 Experimental setting. (A) Thirty-two ApoE−/−-mice and 12 ApoE−/−/AT1R−/−-mice were rendered diabetic after injections of
streptozotocin. The same quantity of ApoE−/− and ApoE−/−/AT1R−/−-mice received vehicle alone and served as non-diabetic controls. Diabetic
and non-diabetic ApoE−/−-mice were further randomized in groups of 8 animals to receive telmisartan, GW9662, telmisartan and GW9962 or
vehicle for 18 weeks. Diabetic and non-diabetic ApoE−/−/AT1R−/−-mice were further randomized in groups of 6 animals to receive either GW9662
or vehicle for 18 weeks. (B) After treatment of 18 weeks mice were sacrificed and read-outs were performed.
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are expressed as lipid-staining area in percent of total sur-
face area. The investigator who performed the histological
analyses was unaware of the hypothesis of this study and
the treatment of the respective animal group.
Measurement of vascular reactive oxygen species
ROS release in intact aortic segments was determined by
L-012 chemiluminescence, as previously described [5].
Chemiluminescence was assessed over 15 minutes in a
scintillation counter (Lumat LB 9501, Berthold) at
1-minute intervals. The vessel segments were then
dried, and dry weight was determined. ROS release is
expressed as relative chemiluminescence per milligram
of aortic tissue.
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis
was performed using the ANOVA test followed by the
Neuman–Keuls post hoc analysis. P < 0.05 indicates stat-
istical significance.Results
Blood pressure, heart rate and metabolic parameters
Total cholesterol levels, fasting blood glucose, change in
body weight, blood pressure and heart rate were mea-
sured in all groups (Table 1). Mice were treated as
described in the method section and depicted in
Figure 1A and Figure 1B. Blood pressure (mmHg) and
heart rates (bpm) were measured in all groups by tail-
cuff measurements. After 18 weeks systolic blood pres-
sure was reduced in ApoE−/−/AT1−/−-mice compared to
ApoE−/−-mice. Heart rates were significant higher in dia-
betic animals. Measurements of fasting blood glucose
levels showed pathological glucose levels in diabetic
animals compared to non-diabetic animals. GW9662
treatment in diabetic ApoE−/− and diabetic ApoE−/−/
AT1−/−-mice resulted in the highest elevation of fasting
blood glucose levels. Cotreatment with telmisartan and
GW9662 markedly attenuated this effect in diabetic
ApoE−/−-mice. Diabetic ApoE−/−-mice treated with tel-
misartan and diabetic ApoE−/−/AT1−/−-mice showed the
lowest fasting blood glucose levels compared to the












Vehicle (n = 8) 29 ± 3*,# 23 ± 1*,# −5,2 ± 0.5*,# 124 ± 4# 992 ± 32*
Telmisartan (n = 8) 31 ± 5* 19 ± 1* −6,9 ± 0.3* 132 ± 9 710 ± 91
Telmi + GW9662 (n = 7) 48 ± 7*‡ 22 ± 0.5* −3.4 ± 0.6* 124 ± 5 887 ± 66*
GW9662 (n = 7) 72 ± 12*,#,‡ 32 ± 1*,#,‡ −12.4 ± 0.6*,#,‡ 123 ± 7# 1040 ± 55*,#
Diabetic ApoE/AT1−/−
Vehicle (n = 6) 15 ± 5* 12 ± 1* 12.6 ± 0.7* 106 ± 2 884 ± 70
GW9662 (n = 6) 17 ± 3* 19 ± 2*,# −5.9 ± 0.9*,# 106 ± 4 772 ± 38
Non-diabetic ApoE−/−
Vehicle (n = 8) 20 ± 2 5 ± 0.2 46 ± 0.8 123 ± 3 649 ± 38
Telmisartan (n = 8) 21 ± 3 5 ± 0.4 40 ± 0.3 118 ± 4 727 ± 21
Telmi + GW9662 (n = 8) 22 ± 2 5 ± 0.3 42 ± 0.5 125 ± 4 708 ± 42
GW9662 (n = 8) 18 ± 1 4 ± 0.4 48 ± 0.3 131 ± 3 695 ± 13
Non-diabetic ApoE/AT1−/−
Vehicle (n = 6) 8 ± 3 5 ± 1 47 ± 0.6 102 ± 5* 742 ± 46
GW9662 (n = 6) 8 ± 3 4 ± 1 50 ± 0.5 105 ± 5* 679 ± 50
To determine cardio-metabolic effects systolic BP, heart rate, fasting blood glucose levels, change in body weight and total cholesterol levels were assessed in
vehicle treated diabetic and non-diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice. *P < 0.05 vs. non-diabetic groups. #p < 0.05 vs. corresponding diabetic
ApoE−/−/AT1R−/−. ‡P < 0.05 vs. vehicle treated diabetic ApoE−/−, n = 6-8 per group.
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was identical in all groups (data not shown). After 18
weeks of standard chow diet, all groups of diabetic
ApoE−/−-mice had significant more loss of body
weight than the corresponding groups of diabetic
ApoE−/−/AT1R−/−-mice. Administration of GW9662
led to a significant decrease in body weight in diabetic
ApoE−/− and diabetic ApoE−/−/AT1R−/−-mice com-
pared to vehicle treated diabetic ApoE−/− and diabetic
ApoE−/−/AT1R−/−-mice. Interestingly, GW9662 treated
diabetic ApoE−/−-mice lost significant more body weight
then GW9662 treated diabetic ApoE−/−/AT1R−/−-mice. In
contrast, all groups of non-diabetic ApoE−/−-mice and
non-diabetic ApoE−/−/AT1R−/−-mice had a uniform incre-
ment in body weight after 18 weeks. Total cholesterol
levels were higher in diabetic ApoE−/−-mice and diabetic
ApoE−/−/AT1−/−-mice compared to non-diabetic groups.
Highest total cholesterol levels were detected in GW9662
treated diabetic ApoE−/−-mice, indicating poor glucose
metabolism and increased lipolysis in GW9662 treated
diabetic ApoE−/−-mice. Co-treatment with telmisartan
reduced this effect significantly. GW9662 had no effect in
diabetic ApoE−/−/AT1−/−-mice. All parameters are shown
in Table 1.
Vascular function
Vascular function was assessed in isolated aortic ring pre-
parations. In contrast to diabetic ApoE−/−/AT1R−/−-mice,endothelium dependent vasodilatation was significantly
impaired in diabetic ApoE−/−-mice indicating that AT1R-
deficiency attenuates endothelial dysfunction in diabetic
animals. Endothelium-dependent vasodilatation was signifi-
cantly impaired in GW9662 treated diabetic ApoE−/−-mice,
whereas treatment with telmisartan led to a significant
improvement of endothelium-dependent vasodilatation.
Cotreatment with GW9662 abolished the beneficial effect
of telmisartan on endothelial function (Figure 2A). In non-
diabetic ApoE−/−-mice treated with vehicle or telmisartan
or telmisartan and GW9662 endothelial function was not
significantly affected (Figure 2B). Endothelium independent
vasorelaxation induced by nitroglycerin was similar in all
groups (data not shown). In addition, vasoconstriction
induced by phenylephrine or KCL was similar in all groups
(data not shown).
Vascular oxidative stress
Vascular release of ROS radicals was measured by L012-
chemiluminescence assays in intact aortic segments.
Figure 3A and Figure 3B illustrate that vascular ROS release
was significantly higher in diabetic animals than in non-
diabetic animals. Diabetic ApoE−/− -mice had significantly
higher ROS levels than diabetic ApoE−/−/AT1R−/−-mice.
AT1R-deficiency in diabetic ApoE−/−-mice and telmisartan
treatment in diabetic ApoE−/−-mice significantly decreased
vascular ROS release. Co-administration of GW9662 abol-
























































































Figure 2 Vascular function. After 18 weeks aortic segments of diabetic (A) and non-diabetic (B) ApoE−/− and ApoE−/−/AT1R−/−-mice were
isolated and their functional performance was assessed in organ chamber experiments. Endothelium-dependent vasodilation induced by
carbachol is shown. Diabetic ApoE−/−-mice displayed severe impairment of endothelial function compared to ApoE−/−/AT1R−/−-mice and
telmisartan-treated ApoE−/−-mice. Treatment of diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice with GW9662 antagonized the protective vascular
effects of AT1R deficiency or AT1 antagonism. *P < 0.05 vs. diabetic ApoE−/−, #P < 0.05 vs. diabetic ApoE−/−/AT1R−/− and ‡P < 0.05 vs diabetic













































































































Figure 3 Oxidative stress. Vascular ROS formation in isolated
aortic segments of diabetic (A) and non-diabetic (B) ApoE−/− and
ApoE−/−/AT1R−/−-mice were assessed by L-012 chemiluminescence.
Diabetic ApoE−/−-mice showed enhanced oxidative stress compared
to ApoE−/−/AT1R−/−-mice and telmisartan-treated ApoE−/−-mice.
Treatment of diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice with
GW9662 raised the levels of oxidative stress to the range found in
diabetic ApoE−/−-mice. *P < 0.05 vs. diabetic and non-diabetic ApoE−/−,
#P < 0.05 vs. diabetic and non-diabetic ApoE−/−/AT1R−/−,
‡P < 0.05 vs diabetic ApoE−/− + GW9662, n = 6-8 per group.
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(Figure 3A). In non-diabetic animals AT1R-deficiency and
treatment with telmisartan reduced vascular ROS release in
a comparable fashion (Figure 3B).
Atherosclerotic lesion formation
Development of atherosclerotic lesions was quantified
in diabetic and non-diabetic animals using oil red O-
staining and macroscopic analysis of the aortic root
after 18 weeks. Figure 4A-F and Figure 4H-M shows
representative aortic root preparations of the different
groups of animals. In contrast to vehicle treated non-
diabetic ApoE−/−-mice (Figure 4H), vehicle treated dia-
betic ApoE−/−-mice (Figure 4A) displayed more athero-
sclerosis in the aortic root. In age-matched diabetic and
non-diabetic ApoE−/−/AT1R−/−-mice, atherosclerotic
lesions were significantly diminished (Figure 4B and 4I).
Concurrent with the significantly improved endothelial
function in telmisartan-treated diabetic ApoE−/−-mice
(Figure 4C), a significant reduction in atherosclerotic
lesion formation was observed compared to vehicle
treated diabetic animals. Application of GW9662 in
diabetic ApoE−/−-mice showed pronounced atheros-
clerotic lesion formation (Figure 4E). Co-administration
of GW9662 and telmisartan attenuated this effect
(Figure 4D). In addition, application of GW9662 signifi-
cantly increased atherosclerotic lesion formation in
diabetic ApoE−/−/AT1R−/−-mice (Figure 4F) compared
to vehicle treated diabetic ApoE−/−/AT1R−/−-mice
(Figure 4I). PPARγ inhibition in GW9662 treated dia-
betic ApoE−/−-mice in the highest extent of atheroscler-
otic lesion formation (Figure 4. In non-diabetic mice
(Figure 4H-N) atherosclerotic lesion formation was sig-








































































































































Figure 4 Atherosclerotic lesion formation. Diabetic and non-diabetic ApoE−/−-mice were treated 18 weeks with telmisartan, GW9662,
telmisartan and GW9662 or vehicle, whereas diabetic and non-diabetic ApoE−/−/AT1R−/−-mice treated with GW9662 or vehicle. Representative
histological cross-sections of the aortic root were stained with oil red O to analyse atherosclerotic plaque development, Figure 4A-F (diabetic
animals) and Figure 4H-M (non-diabetic animals). Quantitative analysis of atherosclerotic lesion formation indicated as plaque area in % of total
area is depicted in Figure 4G (diabetic animals) and Figure 4N (non-diabetic animals). Diabetic ApoE−/−-mice displayed increased atherosclerotic
lesion formation. AT1R-deficiency and telmisartan treatment in ApoE−/−-mice resulted in a significantly reduced area of atherosclerotic lesions,
whereas GW9662 antagonized the atheroprotective effects of AT1R deficiency or AT1 antagonism. *P < 0.05 vs. diabetic and non-diabetic ApoE−/−,
#P < 0.05 vs. diabetic ApoE−/−/AT1R−/−, ‡P < 0.05 vs diabetic and non diabetic ApoE−/− + GW9662, n = 6-8 per group.
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ered atherosclerotic plaque burden in non-diabetic
ApoE−/−/AT1R−/−-mice compared to non-diabetic
ApoE−/−-mice, indicating that AT1R-deficiency results
in decreased atherogenesis not only in diabetic but
also in non-diabetic conditions. Subgroup analysis in
non-diabetic mice indicated that treatment with telmisar-
tan led to reduced atherosclerotic lesion formation in
ApoE−/−-mice (Figure 4J), whereas GW9662 (Figure 4L)
application showed a tendency towards more atherogen-
esis. Importantly, as in diabetic animals, AT1R-deficiency
mediated significant atheroprotective effects in non-
diabetic animals. Vehicle treated ApoE−/−/AT1R−/−-mice
(Figure 4I) had significantly reduced plaque burden com-
pared to ApoE−/− controls (Figure 4H). GW9662 treated
ApoE−/−/AT1R−/−-mice (Figure 4M) had significant less
atherosclerotic plaques than ApoE−/−-mice treated withGW9662 (Figure 4E). Quantitative analysis of atheroscler-
otic lesion formation in diabetic and non-diabetic animals
is shown in Figure 4G, Figure 4N and in Additional file 1:
Table S1.
Discussion
The present study demonstrates the major role of the
AT1R in diabetes-induced atherogenesis. Here we show
that AT1R blockade using a pharmacological approach
and AT1R deficiency by gene deletion attenuates athero-
sclerosis and improves endothelial function in diabetic
and non-diabetic ApoE−/−-mice. In addition, we show for
the first time that the antiatherosclerotic effects of AT1R-
inhibition are in part mediated via PPARγ in vivo. PPARγ-
inhibition by GW9662 treatment resulted in enhanced
ROS generation and atherosclerotic lesion formation in
comparison to untreated diabetic ApoE−/−/AT1R−/−-mice.
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activated receptors, which control the expression of vari-
ous genes attributed with potentially vasoprotective effects
such as improved glucose metabolism, lipid homeostasis
and reduction of oxidative stress [17,18]. Interestingly,
PPARγ affects the expression of the AT1 receptor in vas-
cular cells in vitro. Several authors investigated this issue
in vascular smooth muscle cells and reported a downregu-
lation of AT1 receptor expression on the transcriptional
level following stimulation of PPARγ [14]. Tham et al.
analysed the effects of AT1 receptor activation in respect
to PPARγ expression in vitro and in vivo and reported a
downregulation of PPARγ expression following stimula-
tion with Ang II [19]. This mutual interaction is stressed
by clinical observations in patients with metabolic syn-
drome defined by the coincidence of arterial hypertension
and impaired glucose homeostasis [20]. Hypertension and
the development of diabetes mellitus might interfere
much closer than presently anticipated and the suggested
interlocking regulation of PPARy and the AT1 receptor
might be the key factor in this respect. On the other hand
this interaction might explain why the use of Ang II block-
ers is associated with improved glucose metabolism.
PPARγ activation by PPARγ-agonists induces vascular
protection through the improvement of lipid metabolism,
anti-inflammation and anti-proliferation [10,18,21]. How-
ever, the role of the RAAS in mediating vascular protect-
ive effects of PPARγ-agonists is presently not fully
understood, particular not in metabolic condition of dia-
betes [22].
One characteristic of the PPARs is that their activation
can occur through a broad spectrum of ligands even with
rather low affinity [23]. This implies that particular care
must be taken when assessing the PPARγ-dependence
of AT1R-signaling-pathway. Signalling pathway connected
with PPARγ activation have been investigated in a variety
of recent publications [24]. Focussing on vascular inflam-
mation Ji and coworkers [18] found that PPARγ agonist
treatment of vascular cells in vitro and in vivo significantly
reduced proinflammatory effects of Ang II. The modula-
tory effects of PPARγ were related to diminished activation
of the proinflammatory toll-like receptor 4 (TLR4). TLR4
in turn has been attributed with consecutive activation of
the IP10/PKC/NF-kB pathway. In contrast to Sugawara
et al. PPARγ activation did not affect AT1 receptor expres-
sion but significantly reduced AT1 receptor dependent
ERK1/2 regulation [14]. Studies published by other authors
support the relevant role of the AngII/TLR4-axis in this
respect [25].
Our results emphasize that AT1R-PPARγ-interactions
are in part responsible for atheroprotective effects of
AT1R-deficiency. Application of the specific PPARγ-
antagonist GW9662 in diabetic ApoE−/−/AT1R−/−-mice
resulted in enhanced ROS generation and atherogenesis incomparison to untreated diabetic ApoE−/−/AT1R−/−-mice.
However, the here demonstrated ability of GW9662 to in-
hibit PPARγ does not rule out occurrence of a mechanism
independent of PPARγ-inhibition or counteracting AT1R-
action by altering its signaling cascade olbeit in the litera-
ture, GW9662 has not been associated with pleiotropic
pharmacological effects independent of PPARγ-inhibition
or associated with AT1R-interference.
Diabetes mellitus is associated with a profound risk of
developing atherosclerosis and its complications such as
myocardial infarction [26], stroke [27] and peripheral
vascular disease [28]. In patients with diabetes, athero-
sclerotic lesion progression is accelerated if compared
to the non-diabetic population [29]. ARBs have recently
been shown to prevent the onset of diabetes in hyper-
tensive patients and to reduce cardiovascular and renal
disease progression in diabetic patients with hyper-
tension [30-36]. Whether a specific AT1 Blocker shows
higher levels of PPARγ agonism and whether this effect
results in a clinical benefit remains an unsolved ques-
tion. Our data showed that telmisartan improved oxida-
tive stress, endothelial function and atherosclerosis
while GW9662 treatment showed increased ROS levels
with deleterious effects on endothelial function and ath-
erosclerosis. These effects are much more pronounced
in diabetic animals compared to non-diabetic animals.
This diabetes-dependent aggravation might be partly
related to the diabetes-specific over-activation of the
RAAS.
In conclusion, AT1R-deficiency or pharmacological in-
hibition of the AT1R and activation of PPARγ with telmi-
sartan in diabetic individuals have beneficial effects on
oxidative stress, endothelial function and atherosclerotic
plaque development especially in metabolic and RAAS
abnormalities associated with diabetes indicating to a rele-
vant interaction of PPARγ and the RAAS in vivo. These
findings suggest a potential utility of AT1R inhibitors with
partial PPARγ agonistic activity in the prevention and
treatment of diabetic macrovascular complications.Additional file
Additional file 1: Table S1. Absolute values of endothelial funktion,
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